text: Early ERCP is considered safe as well as cost-effective in the treatment of mild to moderate ascending cholangitis
option_0: Ascending cholangitis cost-effectiveness of therapy
option_1: Gallstone disease cost-effectiveness of therapy
option_2: Cholangitis cost-effectiveness of therapy
option_3: Ascending cholangitis future or investigational therapies
option_4: Spontaneous bacterial peritonitis cost-effectiveness of therapy
option_5: Ascending cholangitis medical therapy
option_6: Cirrhosis cost-effectiveness of therapy
option_7: Hepatocellular carcinoma cost-effectiveness of therapy